(Reuters) - Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent. Allergan has ...

Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's ABBV.N Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics RVNC.O of taking its confidential data to ...

(Reuters) - Warner Chilcott US Sales LLC, now part of Botox maker Allergan Plc, agreed to plead guilty to felony health care fraud and pay $125 million to resolve U.S. charges that it paid kickbacks ...

Warner Chilcott US Sales LLC, now part of Botox maker Allergan Plc, agreed to plead guilty to felony health care fraud and pay $125 million to resolve U.S. charges that it paid kickbacks to doctors to ...

Allergan is looking into strategic options for its women’s heath unit amid a financial slump driven by heightened competition for its best-selling skin and eye drugs, unnamed sources told Bloomberg.

Allergan Inc.’s move into medical cosmetics,wrinkle removers, an obesity device and breast implants,has a name. Earlier this month, the Irvine drug maker unveiled a new division, Allergan Medical, ...

The current stock price likely implies Botox declines, but we think the franchise can maintain healthy growth as a result of expansion of the market and limited price competition. Firms Likely to Have ...

The FINANCIAL — Allergan plc on May 23 announced that the Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista (Allergan’s botulinum toxin type A product) as ...

Competition has arrived for Irvine-based Allergan Inc.? blockbuster wrinkle-remover Botox, but Chief Executive David Pyott plans few changes in his marketing of the drug. At the end of April, Allergan ...

BOTOX® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety ...

–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). –Results support onabotulinumtoxinA as a ...

Allergan Inc. said Tuesday that it will spin off the eye-care business that built the company and allowed it to develop popular skin-care and drug products, which now will become the core of the ...